

Kyowa Hakko Kirin Co., Ltd.**Appendix to the Fiscal 2012 Consolidated Financial Statements**

(January 1, 2012 - December 31, 2012)

Index	Page
I. Consolidated Financial Results	
1. Income	1
2. Results by segment	1
3. Non-operating income/expenses	2
4. Extraordinary income/loss	2
5. R&D expenses	3
6. Capital expenditure	3
7. Depreciation expenses	3
8. Employee numbers	3
9. Exchange rates	3
II. Consolidated Subsidiaries and Affiliates	4
III. Non-Consolidated Net Sales by Division	5
1. Kyowa Hakko Kirin	5
2. ProStrakan	6
3. Kyowa Hakko Bio	6
R&D Pipeline	7

This document was made as a supplement to the Kessan Tanshin (financial report) for the fiscal year ending December 31, 2012. This document contains forward-looking statements based on a number of assumptions and beliefs made by management in light of information currently available. For a variety of reasons, actual financial results may differ materially from the forecasts presented here.

I. Consolidated Financial Results

1. Trends in income

Millions of yen, rounded down

	FY 2011 results		FY 2012 results					FY 2013 forecasts	
	January 1 to June 30	January 1 to December 31 (A)	January 1 to June 30	January 1 to December 31 (forecast as at 7/19)	January 1 to December 31 (B)	Change		January 1 to June 30	January 1 to December 31
						Amount (B-A)	%		
Net sales	186,367	343,722	166,290	333,000	333,158	(10,564)	97%	169,000	338,000
Gross Profit	100,234	197,555	104,321	-	210,690	13,135	107%	-	-
Selling, general and administrative expenses	70,297	150,940	78,736	-	157,785	6,845	105%	-	-
Operating income (prior to amortization of goodwill)	34,576	55,881	30,212	61,255	62,159	6,278	111%	33,627	64,254
Operating income	29,936	46,614	25,585	52,000	52,905	6,290	113%	29,000	55,000
Other income	1,316	2,233	1,419	-	4,167	1,933		-	-
Other expenses	1,040	2,093	3,909	-	8,070	5,977		-	-
Ordinary income	30,212	46,754	23,094	46,500	49,001	2,246	105%	-	49,000
Extraordinary income	8,421	7,332	-	-	-	(7,332)		-	-
Extraordinary expenses	5,363	7,903	324	-	3,976	(3,927)		-	-
Net income before income taxes	33,270	46,183	22,769	45,500	45,025	(1,158)	97%	-	52,000
Corporate, local and enterprise taxes	15,507	20,489	11,212	-	20,609	120		-	-
Income from minority interests	44	86	32	-	215	129		-	-
Net income	17,718	25,608	11,523	23,000	24,199	(1,408)	94%	-	30,000
Comprehensive income	16,745	18,693	13,356	-	34,709	16,016	186%	-	-
EPS before goodwill amortization (#/share)	39.24	61.50	29.40	58.81	61.00	(0.51)	99%	-	71.71

Notes : 1. Figures before goodwill amortization represent amounts prior to subtraction of the goodwill amortization* which occurred as a result of the reverse acquisition (exchange of Kirin Pharma Co. stock) implemented in April 2008.

2. On April 21, 2011, Kyowa Hakko Kirin acquired all outstanding shares of ProStrakan Group plc and as a result ProStrakan Group, and its ten subsidiaries were newly included in the scope of consolidation. In terms of accounting treatment, June 30, 2011 will be considered as the date that the acquisition was completed and therefore results from ProStrakan have not been included in the consolidated financial results for the first half of the current fiscal year. Financial results from ProStrakan and its 10 subsidiary companies as of July have been included in the January to December financial results for 2011.

2. Trends in results by segment

(1) Results by operating segment

Millions of yen, rounded down

	FY 2011 results		FY 2012 results					FY 2013 forecasts	
	January 1 to June 30	January 1 to December 31 (A)	January 1 to June 30	January 1 to December 31 (forecast as at 7/19)	January 1 to December 31 (B)	Change		January 1 to June 30	January 1 to December 31
						Amount (B-A)	%		
Net sales	186,367	343,722	166,290	333,000	333,158	(10,564)	97%	169,000	338,000
Pharmaceuticals	112,534	229,339	122,833	248,000	249,891	20,551	109%	126,000	251,000
Bio-Chemicals	40,360	77,563	40,082	79,000	76,966	(597)	99%	40,000	81,000
Chemicals	33,550	33,550	-	-	-	(33,550)	-	-	-
Other	5,306	10,659	5,173	10,000	10,429	(230)	98%	5,000	10,000
Total	191,752	351,113	168,088	337,000	337,286	(13,826)	96%	171,000	342,000
Eliminations	(5,384)	(7,390)	(1,798)	(40,000)	(4,127)	3,262	56%	(2,000)	(4,000)
Operating income	29,936	46,614	25,585	52,000	52,905	6,290	113%	29,000	55,000
<i>*Before goodwill amortization</i>	34,576	55,881	30,212	61,255	62,159	6,278	111%	33,627	64,254
Pharmaceuticals	25,145	41,314	23,364	48,700	50,392	9,077	122%	25,500	49,000
	29,459	49,942	27,678	57,329	59,020	9,077	118%	29,814	57,628
Bio-Chemicals	2,519	2,896	2,040	3,000	2,127	(768)	73%	3,400	5,800
	2,832	3,521	2,353	3,626	2,753	(768)	78%	3,713	6,426
Chemicals	2,135	2,135	-	-	-	(2,135)	-	-	-
	2,147	2,147	-	-	-	(2,147)	-	-	-
Other	148	360	155	300	338	(21)	94%	100	200
	148	360	155	300	338	(21)	94%	100	200
Total	29,948	46,706	25,560	52,000	52,859	6,152	113%	29,000	55,000
	34,588	55,973	30,187	61,255	62,113	6,139	111%	33,627	64,254
Eliminations	(12)	(92)	24	-	46	138	-	-	-

Notes: 1. Figures representing amounts before goodwill amortization have been italicized.

2. The Chemicals Business was discontinued at the end of the first quarter following the transfer of all shares of Kyowa Hakko Chemical on March 31, 2011. As a result, income from Chemicals was consolidated on the Statements of Income only until March 31, 2011.

(2) Regional sales

Millions of yen, rounded down

	FY 2011 results				FY 2012 results			
	January 1 to June 30	Percentage of consolidated sales	January 1 to December 31	Percentage of consolidated sales	January 1 to June 30	Percentage of consolidated sales	January 1 to December 31	Percentage of consolidated sales
Japan sales	148,987	79.9%	272,568	79.3%	128,898	77.5%	260,524	78.2%
Overseas sales	37,379	20.1%	71,154	20.7%	37,391	22.5%	72,633	21.8%
America	10,456	5.6%	20,071	5.8%	10,097	6.1%	21,207	6.4%
Europe	10,919	5.9%	25,169	7.3%	16,927	10.2%	30,997	9.3%
Asia	15,772	8.5%	25,426	7.4%	10,088	6.1%	19,880	6.0%
Other regions	231	0.1%	486	0.1%	278	0.2%	548	0.2%
Total consolidated net sales	186,367	100.0%	343,722	100.0%	166,290	100.0%	333,158	100.0%

* Sales classified by region or country based on location of customer.

3. Trends in non-operating income/expenses

Millions of yen, rounded down

	FY 2011 results		FY 2012 results	
	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31
Non-operating income	1,316	2,233	1,419	4,167
Interest income	193	497	285	604
Dividends income	303	536	442	993
Foreign exchange gains	112	-	-	1,224
Gain on revaluation of derivatives	-	-	16	-
Income from investment in equity method	141	199	-	-
Other	565	1,000	675	1,343
Non-operating expenses	1,040	2,093	3,909	8,070
Interest expenses	77	135	81	205
Foreign exchange loss	-	154	45	-
Loss on revaluation of derivatives	32	142	-	784
Loss from investment in equity method	-	-	2,549	4,861
Loss on disposal of non-current assets	313	670	414	874
Other	617	990	818	1,344

4. Trends in extraordinary income / loss

Millions of yen, rounded down

	FY 2011 results		FY 2012 results	
	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31
Extraordinary income	8,421	7,332	-	-
Gain on sales of affiliates' stocks	8,320	7,217	-	-
Reversal of allowance for doubtful accounts	100	115	-	-
Extraordinary loss	5,363	7,903	324	3,976
Impairment loss	200	769	-	1,341
Loss on liquidation of affiliates	209	209	-	1,035
Loss on valuation of investment securities	3,043	2,374	-	1,007
Loss on sale of investment securities	-	692	324	344
Loss from business restructuring	-	-	-	247
Advisory fee	1,030	1,098	-	-
Loss on disaster	302	650	-	-
Loss from sale of fixed assets	-	635	-	-
Non-recurring depreciation on non-current assets	-	477	-	-
Loss on adjustment for changes of accounting standard for asset retirement	447	447	-	-
Loss on business liquidation	-	419	-	-
Provision for point card certificates for prior periods	128	128	-	-

5. Trends in R&D Expenses

Billions of yen, rounded down

	FY 2011 results		FY 2012 results		FY 2013 forecasts	
	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31
R&D expenses (Consolidated)	22.2	47.9	22.1	44.8	22.2	44.0
R&D to net sales ratio	11.9%	14.0%	13.3%	13.4%	13.2%	13.0%
Pharmaceuticals (R&D to net sales ratio)	20.4 18.2%	44.5 19.4%	20.5 16.8%	41.3 16.6%	20.5 16.3%	40.7 16.2%
Bio-Chemicals	1.5	3.2	1.5	3.4	1.7	3.3
Chemicals	0.2	0.2	-	-	-	-
Other	-	-	-	-	-	-

6. Trends in Capital Expenditure (Tangible fixed assets)

Billions of yen, rounded down

	FY 2011 results		FY 2012 results		FY 2013 forecasts	
	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31
Capital expenditure (Consolidated)	5.9	14.3	7.9	19.7	7.4	19.2
Pharmaceuticals	2.8	6.5	4.0	10.3	3.7	9.5
Bio-Chemicals	2.7	7.4	3.9	9.4	3.7	9.7
Chemicals	0.3	0.3	-	-	-	-
Other	0.0	0.0	0.0	0.0	0.0	0.0

7. Trends in Depreciation Expenses

Billions of yen, rounded down

	FY 2011 results		FY 2012 results		FY 2013 forecasts	
	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31
Depreciation expenses (Consolidated)	10.4	22.8	9.6	20.9	9.9	21.2
Pharmaceuticals	6.8	15.3	6.6	14.5	6.7	14.6
Bio-Chemicals	2.6	6.4	2.9	6.2	3.1	6.6
Chemicals	0.9	0.9	-	-	-	-
Other	0.0	0.0	0.0	0.0	0.0	0.0

8. Trends in Employee Numbers

	FY 2011	FY 2012
	December 31	December 31
Number of staff at end of term (Consolidated)	7,229	7,243
Pharmaceuticals	5,390	5,374
Bio-Chemicals	1,632	1,668
Other	207	201

9. Exchange rates

	FY 2011 results		FY 2012 results		FY 2013 forecasts	
	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31
US Dollar (¥/US\$)	82	80	80	80	85	85
Euro (¥/Euro)	115	111	103	103	115	115
Pound (¥/Pound)	133	128	126	127	140	140

II. Consolidated Subsidiaries and Affiliates

(As of December 31, 2012)

Segment	Type	Region	Company name	Percentage owned (direct and indirect)	Principal business
Pharmaceuticals	Consolidated subsidiary	Japan	Kyowa Medex Co., Ltd.	100.0%	Manufacture and sale of diagnostic reagents
			Kyowa Medical Promotion Co., Ltd.	100.0%	Promotion and sales of pharmaceuticals
		The Americas	Kyowa Hakko Kirin America, Inc.	100.0%	Holding company for administration and management of subsidiaries (US)
			BioWa, Inc.	100.0%	Out-licensing of anti-body technology (US)
			Kyowa Hakko Kirin Pharma, Inc.	100.0%	Development of outsourced pharmaceutical products (US)
			Kyowa Hakko Kirin California, Inc.	100.0%	Generate new candidate substances and develop pharmaceuticals (US)
			Hematech, Inc.	100.0%	Technology research for manufacture of therapeutic antibody (US)
			ProStrakan Inc.	100.0%	Sales of pharmaceuticals (US)
		Europe	ProStrakan Group plc	100.0%	Supervision and management of special companies (UK)
			Strakan International S.a r.l.	100.0%	Sales, licensing-in and licensing-out of pharmaceuticals (UK)
			Strakan Pharmaceuticals Limited	100.0%	Development of pharmaceuticals (UK)
			ProStrakan Limited	100.0%	Sales of pharmaceuticals (UK)
			ProStrakan Pharma S.A.S	100.0%	Sales of pharmaceuticals (France)
			ProStrakan Farmaceutica SLU	100.0%	Sales of pharmaceuticals (Spain)
			ProStrakan Pharma GmbH	100.0%	Sales of pharmaceuticals (Germany)
			ProStrakan Holdings B.V.	100.0%	Holding company for special companies (Netherlands)
			ProStrakan Pharma B.V.	100.0%	Sales of pharmaceuticals (Netherlands)
			ProStrakan S.r.l.	100.0%	Sales of pharmaceuticals (Italy)
		ProStrakan AB	100.0%	Sales of pharmaceuticals (Sweden)	
	Asia	Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.	100.0%	Manufacture and sale of pharmaceuticals (China)	
Kyowa Hakko Kirin Korea Co., Ltd.		100.0%	Sales of pharmaceuticals (Korea)		
Kyowa Hakko Kirin (Taiwan) Co., Ltd.		100.0%	Sales of pharmaceuticals (Taiwan)		
Kyowa Hakko Kirin (Hong Kong) Co., Ltd.		100.0%	Sales of pharmaceuticals (Hong Kong)		
Kyowa Hakko Kirin (Singapore) Pte. Ltd.		100.0%	Sales of pharmaceuticals (Singapore)		
Affiliate accounted for by the equity method	Japan	FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.	50.0%	Development, manufacture and sale of biosimilar pharmaceuticals	
Bio-Chemicals	Consolidated subsidiary	Japan	Kyowa Hakko Bio Co., Ltd.	100.0%	Manufacture and sale of pharmaceutical and industrial raw materials, and health care products
			Daiichi Fine Chemical Co., Ltd.	100.0%	Manufacture and sale of active pharmaceutical ingredients and pharmaceutical intermediates
			Kyowa Wellness Co., Ltd.	100.0%	Sale of healthcare products
			Kyowa Engineering Co., Ltd.	100.0%	Design and installation of plant facilities and equipment
		The Americas	BioKyowa Inc.	100.0%	Manufacture and sale of amino acids (US)
			Kyowa Hakko U.S.A., Inc.	100.0%	Sale and import/export of fine chemicals including amino acids (US)
			Kyowa Hakko Bio U.S. Holdings, Inc.	100.0%	Holding company for administration and management of US special companies (US)
		Europe	Kyowa Hakko Europe GmbH	100.0%	Sale and import/export of fine chemicals including amino acids (Germany)
			Kyowa Hakko Bio Italia S.r.l.	100.0%	Sale and import/export of fine chemicals including amino acids (Italy)
		Asia	Shanghai Kyowa Amino Acid Co., Ltd.	70.0%	Manufacture and sale of amino acids (China)
			Thai Kyowa Biotechnologies Co., Ltd.	100.0%	Manufacture and sale of amino acids (Thailand)
			Kyowa Hakko (H.K.) Co., Ltd.	100.0%	Sale and import/export of fine chemicals including amino acids (Hong Kong)
			Kyowa Hakko Bio Singapore Pte. Ltd.	100.0%	Sale and import/export of fine chemicals including amino acids (Singapore)
Other	Consolidated subsidiary	Japan	Chiyoda Kaihatsu Co., Ltd.	100.0%	Distribution, insurance, wholesale and retail
	Affiliate accounted for by the equity method		Japan Synthetic Alcohol Co., Ltd.	33.3%	Manufacture and sale of industrial use alcohol

Notes: Changes to the scope of consolidation (January 1, 2012 to December 31, 2012)

Newly consolidated: 2 companies: ProStrakan AB (*1) Thai Kyowa Biotechnologies (*2)

Removed: 2 companies: Kyowa Hakko Kirin Italia S.r.l. (*3) Hematech-GAC Venture, LLC (*4)

*1 On June 1, 2012, Kyowa Hakko Kirin acquired all outstanding shares of ProStrakan AB which was newly included as a subsidiary in the scope of consolidation.

*2 Thai Kyowa Biotechnologies Co., Ltd. was established on November 12, 2012 and made into a consolidated subsidiary.

*3. On June 1, 2012, Kyowa Hakko Kirin Italia S.r.l. merged with ProStrakan S.r.l. and was eliminated.

*4 Hematech-GAC Venture, LLC was excluded from the scope of consolidation following the transfer of all outstanding shares on December 31, 2012

*5. As of April 23, 2012, Kirin Kunpeng (China) Bio-Pharmaceutical Co., Ltd. changed its corporate name to Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.

*6. As of June 1, 2012, Jeil-Kirin Pharm. Inc. changed its corporate name to Kyowa Hakko Kirin Korea Co., Ltd.

III. Non-Consolidated Net Sales by Division (Items and main products)

1. Kyowa Hakko Kirin

Billions of yen, rounded down

Pharmaceuticals division (non-consolidated)	FY 2011 results		FY2012 results				FY 2013 forecasts	
	January 1 to June 30	January 1 to December 31 (A)	January 1 to June 30	January 1 to December 31 (forecast as at 7/19)	January 1 to December 31 (B)	Change (B/A)	January 1 to June 30	January 1 to December 31
Pharmaceuticals division total	104.6	206.0	107.8	213.9	218.1	106%	108.7	212.3
Indication / Product name								
<i>ESA formulation</i> Nesp	25.4	56.4	26.8	53.7	58.1	103%	27.7	57.8
<i>ESA formulation</i> Espo	2.7	5.3	1.9	4.0	3.9	73%	1.7	3.5
Nesp/Espo	28.2	61.8	28.8	57.7	62.0	100%	29.5	61.3
<i>Secondary hyperparathyroidism</i> Regpara	5.3	11.5	6.2	13.0	13.4	116%	6.7	14.1
<i>Secondary hyperparathyroidism</i> Rocatrol*1	1.5	3.2	1.6	-	3.6	113%	1.8	3.6
<i>Antiallergenic</i> Allelock	18.1	29.1	16.1	29.1	29.9	103%	16.2	27.8
<i>Antiallergenic</i> Celtect	1.3	2.5	1.0	1.8	1.9	75%	1.0	1.8
<i>Antiallergic eyedrops</i> Patanol	8.6	11.4	6.9	10.1	10.2	90%	8.1	11.4
<i>G-CSF</i> Gran	6.7	14.8	6.4	13.4	13.5	92%	6.0	12.6
<i>Cancer pain</i> Fentos	1.2	3.1	2.0	4.5	4.6	148%	2.4	5.5
<i>Anticancer</i> 5-FU	1.5	3.1	1.4	2.7	2.8	90%	1.4	2.8
<i>Anticancer</i> Navelbine	0.8	1.7	0.6	1.2	1.3	76%	0.6	1.1
<i>Chronic idiopathic thrombocytopenic purpura</i> Romiplate *2	0.1	0.7	0.7	-	1.7	243%	0.8	1.8
<i>Cardiovascular</i> Coniel	9.6	19.7	8.5	17.2	17.1	87%	7.6	15.4
<i>Cardiovascular (Hypertension)</i> Coversyl	1.9	3.9	1.7	3.4	3.5	90%	1.5	3.1
<i>Cardiovascular</i> Inovan / Pre Dopa	1.3	2.8	1.1	2.4	2.4	85%	0.9	1.8
<i>Antiepileptic</i> Depakene	5.3	11.2	5.2	10.8	10.7	95%	5.1	10.5
<i>Parkinson's disease</i> Permax	1.1	2.1	0.8	1.7	1.7	78%	0.8	1.7
<i>Gastrointestinal</i> Nauzelin	2.3	4.8	2.2	4.7	4.9	102%	2.4	4.9
<i>Inflammatory bowel disease</i> Asacol	1.1	2.8	1.8	3.8	4.1	142%	2.3	4.8
Exports and Technology Out-Licensing	11.4	22.3	17.9	34.7	34.2	154%	16.0	28.0

*1 On April 1, 2012, manufacturing and sales rights, etc., for Rocatrol were received from Chugai Pharmaceutical

*2 Sales of Romiplate began April 13, 2011

2. ProStrakan

Millions of GBP, rounded down

Pharmaceuticals division	FY 2011 results		FY 2012 results				FY 2013 forecasts	
	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31 (Forecast as at 7/19)	January 1 to December 31	Change (B/A)	January 1 to June 30	January 1 to December 31
Net sales	48	105	61	139	129	123%	74	154
Chemotherapy-induced nausea and vomiting drug Sancuso	4	9	5	16	12	131%	9	19
Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Abstral	12	27	16	36	33	124%	20	42
Replacement therapy with testosterone for male hypogonadism Tostran	2	5	2	4	7	145%	5	11
Prevention and treatment of post-operative nausea and vomiting (PONV). Xomolix	4	8	4	9	8	94%	3	7
Relief of pain associated with chronic anal fissures Rectogesic	4	9	4	9	10	109%	6	12
Osteoporosis drug Adcal-D3	11	24	12	25	26	106%	12	26
Others	8	20	14	37	30	151%	17	33
Gross profit	29	65	40	101	91	140%	56	118
Selling, general and administrative expenses	40	75	39	84	76	102%	47	90
Operating income (prior to consolidated adjustment)	(11)	(9)	1	17	15	-	9	28
Consolidated adjustment			(18)	(34)	(35)		(16)	(32)
Operating income (after consolidated adjustment)			(16)	(17)	(19)		(6)	(4)

Notes:

- The results of ProStrakan were consolidated from July 2011.
- The results of Prostrakan are shown on a local basis (IFRS standards) for fiscal 2011 and on the Kyowa Hakko Kirin standards for fiscal 2012. The consolidated adjustment amounts are mainly the goodwill and amortization of product sales rights associated with the Prostrakan acquisition.
- The sales ratio by region is as shown below.

*Sales ratio by region

(January 1 to December 31, 2012)

UK	Europe (excluding UK)	USA	Other
33.4%	41.8%	22.9%	1.9%

3. Kyowa Hakko Bio

Billions of yen, rounded down







Bio-Chemicals division (non-consolidated)	FY 2011 results		FY 2012 results				FY 2013 forecasts	
	January 1 to June 30	January 1 to December 31 (A)	January 1 to June 30	January 1 to December 31 (forecast as at 7/19)	January 1 to December 31 (B)	Change (B/A)	January 1 to June 30	January 1 to December 31
Bio-Chemical division total	25.9	49.6	25.9	52.1	51.2	103%	28.7	57.2
Pharmaceuticals / Industrial raw materials								
Amino acids	10.1	19.1	10.2	20.6	20.2	106%	11.5	22.6
Nucleic acids and vitamins	2.7	5.2	2.5	5.2	5.2	100%	2.7	5.4
Other	3.8	7.2	3.7	6.6	7.2	99%	3.2	6.5
Health care products	4.7	9.3	4.7	10.1	9.3	100%	6.4	13.1

R&D Pipeline















 antibody
  protein
  small molecule

Filed • Approved

As of Jan 24th 2013

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		KW-2246 Fentanyl citrate Sublingual Tablet	μ -Opioid Receptor Agonist	Cancer Pain	Filed in Japan	Licensed from Orexo	
		Granisetron Patch	5HT ₃ Serotonin Receptor Antagonist	Chemotherapy induced Nausea and Vomiting	Filed in Asia	Solasia Pharma (ProStrakan)	Asia: Singapore, Malaysia and Hong Kong
Nephrology		Cinacalcet Hydrochloride Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Filed in Asia	Licensed from NPS	Asia: Philippine, Malaysia, Thailand and China
		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Pediatric Renal Anemia	Filed in Japan	Kirin- Amgen	
Central Nervous System		©KW-6002 Istradefylline Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	Filed in USA Filed in Japan	In-House	
		KW-6485 Topiramate Oral	Antiepileptic Drug	Pediatric Epilepsy	Filed in Japan	Licensed from Janssen Pharmaceutic al KK	

Phase II, Phase III

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony Stimulating Factor	Chemotherapy induced Febrile Neutropenia	Phase III in Japan	Kirin- Amgen	
		©ARQ 197 Tivantinib Oral	c-Met inhibitor	Lung Cancer (EGF-receptor mutated)	Phase II in Japan	Licensed from ArQuile	
				Gastric Cancer	Phase II in Japan and Korea		
		KW-0761 Mogamulzumab Injection	Anti-CCR4 Humanized Antibody	Peripheral T/NK-cell Lymphoma	Phase II in Japan	In-House	POTELLIGENT*
				Adult T-cell Leukemia/Lymphoma, Add-on Therapy (for Untreated Patients)	Phase II in Japan		
				Peripheral T-cell Lymphoma	Phase II in EU		
				Adult T-cell Leukemia/Lymphoma	Phase II in US and EU		
		KRN1493 Cinacalcet Hydrochloride Oral	Calcium Receptor Agonist	Hypercalcemia with Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism	Phase III in Japan	Licensed from NPS	
		©KW-2478 Injection	HSP90 inhibitor	Multiple Myeloma	Phase I / II in UK/US/PH	In-House	
		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Myelodysplastic Syndrome related Anemia	Phase II in Japan and Korea	Kirin- Amgen	
Nephrology		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	Phase II in China	Kirin- Amgen	
		©RTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	CKD in patients with type 2 diabetes	Phase II in Japan	Licensed from Reata	
Immunology /Allergy		©KHK4563 Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Asthma	Phase II in Japan and Korea	In-House	Being Developed by MedImmune as MEDI-563 Worldwide except in Japan and other Asian Countries POTELLIGENT*
		©ASKP1240 Injection	Anti-CD40 Fully Human Antibody	Organ Transplant Rejection	Phase I in Japan Phase II in USA	In-House	Jointly Developed with Astellas KM mouse
		Z-206 Mesalazine Oral	pH Dependent Controlled Release Tablet	Crohn's Disease	Phase II in Japan	Licensed from Zeria Pharma.	Jointly Developed with Zeria Pharma
		©KHK4827 Injection	Anti-IL-17 Receptor Fully Human Antibody	Psoriasis	Phase II in Japan	Kirin- Amgen	
Central Nervous System		©KHK6188 Oral	Cannabinoid CB2 Receptor Agonist	Neuropathic Pain	Phase II in Japan	In-House	
Other		©KW-3357 Antithrombin Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase III in Japan	In-House	
					Phase I in Europe		

Updated since Oct 18th, 2012 (Area, Stage, Filed, Approved, Launched etc.)

© New Molecular Entity

Phase I

As of Jan 24th 2013

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		©KW-2450 Oral	IGF-1 Receptor Signal Inhibitor	Cancer	Phase I / II in USA	In-House	
		©BIW-8962 Injection	Anti-GM2 Humanized Antibody	Cancer	Phase I / II a in USA	In-House	POTELLIGENT®
		©KRN951 Tivozanib Oral	VEGF Receptor Inhibitor	Cancer	Phase I in Japan	In-House	Filed in US by AVEO as AV-951
		©KHK2866 Injection	Anti-HB-EGF Humanized Antibody	Cancer	Phase I in USA	In-House	POTELLIGENT®
		©LY2523355 Litrnesib Injection	M phase Kinesin Eg5 Inhibitor	Cancer	Phase I in Japan	In-House	Being Developed by Eli Lilly as LY2523355 Worldwide except in Japan
		©CEP-37250/K HK2804 Injection	Anti-Tumor Specific Glycoprotein Humanized Antibody	Cancer	Phase I in USA	Cephalon	Jointly Developed with Cephalon POTELLIGENT®
		©KHK2898 Injection	Anti-CD98 Fully Human Antibody	Cancer	Phase I in Singapore	In-House	POTELLIGENT® KM mouse
		©ARQ 197 Tivantinib Oral	c-Met Inhibitor	Hepatocellular Cancer	Phase I in Japan	Licensed from ArQule	
Nephrology		©KHK7580 Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Phase I in Japan	Mitsubishi Tanabe	
Immunology /Allergy		KW-0761 Mogamulzumab Injection	Anti-CCR4 Humanized Antibody	Asthma	Phase I in Japan	In-House	POTELLIGENT®
		©KHK4083 Injection	Immunomodulator	Autoimmune diseases	Phase I in Canada	In-House	POTELLIGENT® KM mouse
		©KHK4577 Oral	Anti-inflammatory Agent	Inflammatory disease	Phase I in Japan	In-House	
Other		©KRN23 Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemic Rickets/Osteomalacia (XLH)	Phase I / II in USA and Canada	In-House	KM mouse



■ Updated since Oct 18th, 2012 (Area, Stage, Filed, Approved, Launched etc.)

© New Molecular Entity



Updated since Oct 18th, 2012 (Area, Stage, Filed, Approved, Launched etc.)

Filed - Approved




As of Jan 24th 2013

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		KW-2246 Fentanyl citrate Sublingual Tablet	μ -Opioid Receptor Agonist	Cancer Pain	Filed in Japan	Licensed from Orexo	
Central Nervous System		KW-6485 Topiramate Oral	Antiepileptic Drug	Pediatric Epilepsy	Filed in Japan	Licensed from Janssen Pharmaceutic al KK	


Phase II, Phase III

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		KW-0761 Mogamulzumab Injection	Anti-CCR4 Humanized Antibody	Cutaneous T-cell Lymphoma	Phase III in US	In-House	POTELLIGENT®
Immunology /Allergy		©KHK4827 Injection	Anti-IL-17 Receptor Fully Human Antibody	Psoriasis	Phase II in Japan	Kirin- Amgen	

Phase I

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		©KHK7580 Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Phase I in Japan	Mitsubishi Tanabe	
Immunology /Allergy		©KHK4083 Injection	Immunomodulator	Autoimmune diseases	Phase I in Canada	In-House	POTELLIGENT® KM mouse
Immunology /Allergy		©KHK4577 Oral	Anti-inflammatory Agent	Inflammatory disease	Phase I in Japan	In-House	

Study Discontinuation

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Reason
Oncology		©ARQ 197 Tivantinib Oral	c-Met Inhibitor	Lung Cancer (EGF-receptor wild type)	Phase III in Japan, Korea and Taiwan	Licensed from ArQule	Following the safety review committee recommendation by higher frequency of interstitial lung disease cases in the study as one of drug related adverse reactions.